NDAINJECTIONINJECTABLE
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
CEFAZOLIN AND DEXTROSE (cefazolin sodium) by B. Braun is 12. Approved for respiratory tract infections due to streptococcus pneumoniae, staphylococcus aureus, streptococcus pyogenes in adults and 14 more indications. First approved in 2000.
Drug data last refreshed Yesterday
Mechanism of Action
12.1 Mechanism of Action Cefazolin is an antibacterial drug [see ]. 12.2 Pharmacodynamics The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients. 12.3 Pharmacokinetics Studies have shown that following intravenous administration of cefazolin to normal…
Worked on CEFAZOLIN AND DEXTROSE at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.